The firm is an early-stage venture capital firm that primarily invests at the Seed and Series A stages, often serving as the first institutional investor in its portfolio companies. Initial investments typically range from approximately $500K to $7M, with the capacity to invest $15M or more over the life of a company. The firm invests globally but maintains a strong focus on opportunities emerging from major innovation hubs in the United States. The firm follows a thesis-driven investment strategy centered on building category-defining companies addressing large, underserved markets.
Within healthcare, the firm invests in medical technology, medical devices, diagnostics, genomics-enabled diagnostics, bioinformatics platforms, laboratory services, and other data-driven healthcare businesses. The firm seeks disruptive technologies capable of transforming large clinical markets, with particular interest in opportunities addressing diabetes, cardiovascular disease, hypertension, obesity, and other significant unmet healthcare needs. The firm emphasizes scalable business models, differentiated innovation, and the potential to create or redefine large markets.
From a company and management team perspective, the firm frequently serves as the lead or co-lead investor and takes an active board role. The firm works closely with portfolio companies on strategy, executive recruitment, product development, commercialization, and fundraising. While experienced leadership teams are valued, the firm is also willing to back first-time founders who demonstrate exceptional vision, technical expertise, and the ability to execute against large market opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 